Cohen M, Xiong J, Parry G, Adams P C, Chamberlain D, Wieczorek I, Fox K A, McBride R, Chesebro J H, Fuster V
Department of Medicine, Hahnemann University Hospital, Philadelphia, Pennsylvania 19102-1192.
J Am Coll Cardiol. 1993 Nov 1;22(5):1338-43. doi: 10.1016/0735-1097(93)90540-h.
This study was designed to compare the response of unstable angina and non-Q wave myocardial infarction during treatment with antithrombotic therapy.
Antithrombotic therapy is beneficial in patients with these two coronary syndromes.
In a multicenter trial of antithrombotic therapy in unstable angina or non-Q wave myocardial infarction, 358 patients admitted within 48 h of chest pain were randomized to antithrombotic therapy with either 1) aspirin alone, or 2) aspirin plus heparin followed by aspirin plus warfarin, and were prospectively followed up for 12 weeks. Admission cardiac enzyme analyses revealed unstable angina in 268 patients and non-Q wave myocardial infarction in 62. Given an event rate of about 25%, this study has a power of 80% to detect a 50% difference between the two groups.
Patients with unstable angina and non-Q wave myocardial infarction were similar with regard to age, gender, coronary risk factors and prior antianginal medication. Primary end points at 12 weeks were recurrent ischemia, infarction and death. [table: see text] In the non-Q wave group, all infarctions and death occurred within the 1st week.
Patients with unstable angina or non-Q wave myocardial infarction on antithrombotic therapy have a similar total number of ischemic events by 12 weeks. However, despite maximal medical therapy with antianginal and antithrombotic medication, patients with non-Q wave infarction have a significantly higher rate of reinfarction and death.
本研究旨在比较抗栓治疗期间不稳定型心绞痛和非Q波心肌梗死的反应。
抗栓治疗对这两种冠状动脉综合征患者有益。
在一项针对不稳定型心绞痛或非Q波心肌梗死的抗栓治疗多中心试验中,358名在胸痛48小时内入院的患者被随机分为抗栓治疗组,1)单独使用阿司匹林,或2)阿司匹林加肝素,随后阿司匹林加华法林,并进行前瞻性随访12周。入院时心脏酶分析显示,268例患者为不稳定型心绞痛,62例为非Q波心肌梗死。鉴于事件发生率约为25%,本研究有80%的把握度检测两组之间50%的差异。
不稳定型心绞痛和非Q波心肌梗死患者在年龄、性别、冠状动脉危险因素和既往抗心绞痛药物治疗方面相似。12周时的主要终点是复发性缺血、梗死和死亡。[表:见原文]在非Q波组中,所有梗死和死亡均发生在第1周内。
接受抗栓治疗的不稳定型心绞痛或非Q波心肌梗死患者在12周时缺血事件总数相似。然而,尽管使用了抗心绞痛和抗栓药物进行最大程度的药物治疗,非Q波梗死患者的再梗死率和死亡率仍显著较高。